What is Sweetch?
Founded in 2013 and headquartered in Tel Aviv, Sweetch operates at the intersection of behavioral science and digital health. The company provides a clinically validated platform designed to facilitate hyper-personalized engagement for individuals managing chronic conditions. By integrating seamlessly with pharmaceutical workflows, device manufacturers, and healthcare payers, Sweetch enables continuous, real-world patient support. Its technology is engineered to deliver recommendations that are contextually relevant, utilizing a sophisticated blend of AI and EI to ensure that patient interactions occur at the optimal time and tone, thereby driving adherence and improving long-term health outcomes at scale.
The company's market position is defined by its ability to transform static health data into dynamic, actionable behavioral nudges. As the healthcare industry shifts toward value-based care models, Sweetch provides the necessary digital architecture to maintain patient relationships outside of traditional clinical settings, effectively reducing the burden on healthcare providers while enhancing the quality of life for patients.
How much funding has Sweetch raised?
Sweetch has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2021): $20M with participation from Entree Capital, Tal-Cap, Noaber, Kortex Ventures, and FinTLV Ventures
Key Investors in Sweetch
Entree Capital
A venture capital firm that partners with ambitious founders from the earliest stages through to scale-up, providing both financial backing and strategic operational guidance.
Tal-Cap
An investment entity focused on identifying and acquiring viable business opportunities to foster long-term growth and market presence.
Noaber
An institutional investor participating in the funding round, contributing to the strategic development of the company's digital health initiatives.
What's next for Sweetch?
With this major enterprise-level funding, Sweetch is poised to accelerate its commercial expansion and deepen its technological capabilities. The strategic capital will likely be deployed to scale its digital therapeutics platform across new international markets and broaden its integration capabilities with existing enterprise health systems. As the company moves beyond its initial growth phase, the focus will shift toward establishing long-term partnerships with global pharmaceutical entities and large-scale health payers. By refining its AI-driven engagement engine, Sweetch aims to set a new standard for patient-centric care, ensuring that its behavioral science methodology becomes a foundational component of chronic disease management strategies worldwide.
See full Sweetch company page
